Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASAP Switch Study: B/F/TAF for Migrants with HIV
NCT06375304Phase 4Not yet recruiting
- Sponsor
- McGill University Health Centre
- Start
- May 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by McGill University Health Centre. Planned start May 2024; status: not yet recruiting.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06375304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06375304.